biostudies-literatureSeok JMinistry of Health & Welfare, Republic of KoreaMinistry of Health &amp; Welfare, Republic of Korea671https://www.ebi.ac.uk/biostudies/studies/S-EPMC12673732biostudies-literatureUnknown16(1)<h4>Background</h4>Atopic dermatitis (AD) is a chronic skin condition affecting patients' well-being, but conventional treatments have limitations. Mesenchymal stem cells (MSCs) present a promising option for AD therapy, though large-scale clinical studies are scarce. This study aimed to assess the efficacy and safety of autologous adipose tissue-derived MSC (AtMSC) in moderate to severe AD refractory to conventional treatments.<h4>Methods</h4>This multicenter, randomized, single-blind, placebo-controlled, phase 2 trial included 114 participants. Participants received two intravenous injections of AtMSCs or placebo at 4-week intervals. Clinical assessments, comprising Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), and Investigator's Global Assessment (IGA), wereStem cell research & therapyEfficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial.PMC12673732RS-2024-00406957Seo YJKim SYSon SWShin MKPark KYLee DHLee SHSeo JSLee WGCho SSeok JSeo SJfalseEfficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial.<h4>Background</h4>Atopic dermatitis (AD) is a chronic skin condition affecting patients' well-being, but conventional treatments have limitations. Mesenchymal stem cells (MSCs) present a promising option for AD therapy, though large-scale clinical studies are scarce. This study aimed to assess the efficacy and safety of autologous adipose tissue-derived MSC (AtMSC) in moderate to severe AD refractory to conventional treatments.<h4>Methods</h4>This multicenter, randomized, single-blind, placebo-controlled, phase 2 trial included 114 participants. Participants received two intravenous injections of AtMSCs or placebo at 4-week intervals. Clinical assessments, comprising Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), and Investigator's Global Assessment (IGA), were2025-01-01T00:00:00Z2025 Dec2026-06-05T22:20:48.485Z2026-05-22T03:16:14.414ZS-EPMC126737324133172510.1186/s13287-025-04763-y